Speak directly to the analyst to clarify any post sales queries you may have.
The immunohematology market is experiencing significant transformation as technological innovation, regulatory changes, and new standards shape diagnostics, patient safety, and blood management. Senior decision-makers need strategic analysis to navigate an environment defined by operational complexity, competitive shifts, and expanding market opportunities.
Market Snapshot: Immunohematology Market Insights
The immunohematology market advanced from USD 2.22 billion in 2024 to USD 2.40 billion in 2025, demonstrating a robust CAGR of 8.48%, and is projected to achieve USD 4.27 billion by 2032. This sustained growth highlights surging demand for advanced diagnostic systems and ongoing reagent innovation as healthcare providers seek to strengthen transfusion safety, minimize operational errors, and comply with evolving regulatory requirements.
Scope & Segmentation
This report delivers an in-depth view of the immunohematology landscape, allowing leaders to evaluate risks and opportunities across sub-segments, regional markets, and emerging technologies. Understanding these dimensions empowers strategic planning for optimal results.
- Product Types: Includes analyzers and systems, such as fully-automated and semi-automated solutions, as well as reagents and kits designed to support diverse testing protocols.
- Applications: Encompasses antibody screening, blood transfusion management, disease diagnostics, and pregnancy-related assay development tailored to evolving healthcare needs.
- End Users: Targets blood banks, diagnostic laboratories, hospitals, and research institutes operating in varied infrastructure and regulatory scenarios.
- Regional Markets: Covers the Americas, Europe (inclusive of the Middle East and Africa), and Asia-Pacific, each bringing unique adoption patterns, technology trends, and investment drivers to the market.
- Companies Profiled: Features leading firms such as Abbott Laboratories, AliveDx Suisse SA, Beckman Coulter, Bio-Rad Laboratories, Biomed Global, Cardinal Health, DIAGAST, Grifols, Avantor, and QuidelOrtho Corporation.
Key Takeaways for Senior Decision-Makers
- Automation and digital workflow enhancements continue to drive gains in laboratory efficiency, supporting precision and error reduction in immunohematology practice.
- Integration with laboratory information management systems is enabling more seamless data exchange, crucial for effective centralized and distributed operations.
- Developments in molecular immunohematology and genomic profiling are enhancing antigen characterization, advancing personalized medicine and matching practices.
- Collaborative initiatives within the industry—spanning reagent advancements to jointly developed analyzers—are expediting product innovation and market introduction.
- Customizable solutions, from scalable semi-automated analyzers suitable for community health to fully-automated systems for large hospitals, help organizations address both operational scale and compliance needs.
- Competitive advantage is increasingly shaped by focused R&D, robust platform interoperability, remote support capabilities, and digital analytics, which offer long-term value to healthcare institutions.
Tariff Impact: Navigating Regulatory and Cost Challenges
Recent US tariff adjustments have introduced new cost structures into immunohematology supply chains, leading to shifts in sourcing, manufacturing, and inventory management strategies. Stakeholders are prioritizing domestic production and building collaborative supplier partnerships, while adopting just-in-time inventory approaches to maintain continuity and manage escalating costs. These dynamics are influencing automation investment decisions as organizations balance capital spending with operating expense management.
Methodology & Data Sources
The report is grounded in multi-source market analysis, leveraging direct interviews with laboratory leaders, product experts, and regulators. Findings are informed by an evaluation of peer-reviewed studies, clinical guidelines, regulatory documents, manufacturer disclosures, and patent data. Data triangulation and systematic peer review help validate both qualitative and quantitative insights, ensuring reliability for decision-making.
Why This Report Matters
- Equips senior decision-makers to benchmark technology adoption, operational best practices, and vendor capabilities in the rapidly changing immunohematology market.
- Informs strategy by evaluating segment dynamics, regulatory trends, and market positioning across all major geographies.
- Offers actionable guidance to align operational and investment priorities with patient safety, compliance goals, and market growth strategies.
Conclusion
This analysis delivers a comprehensive and actionable overview of the immunohematology market, arming stakeholders with insight to anticipate industry shifts, adapt to regulatory environments, and drive superior outcomes in blood safety diagnostics.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
List of Figures
Samples
LOADING...
Companies Mentioned
The key companies profiled in this Immunohematology market report include:- Abbott Laboratories
- AliveDx Suisse SA
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- Biomed Global
- Cardinal Health, Inc.
- DIAGAST
- Grifols, S.A.
- Avantor, Inc.
- QuidelOrtho Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 197 |
| Published | October 2025 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 2.4 Billion |
| Forecasted Market Value ( USD | $ 4.27 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
